The N-terminal transcriptional activation domain of FUS is fused to the transcription factor CHOP, forming FUS-CHOP,4, 5 which accounts for >90% of myxoid liposarcoma cases.6 Similarly, fusion of FUS with either the transcription factor ERG or FEV has been found in some cases of EWS family tumors7, 8 or acute myeloid leukemia,9, 10 and fusion with ATF1 and either CREB3 L2 or CREB3 L1 will cause angiomatoid fibrous histiocytoma11 and low-grade fibromyxoid sarcoma,12 respectively. This evidence concerns the gene FUS and acute myeloid leukemia.